News and Updates

Finerenone is the First Therapy Approved in 30 Years for Kidney Disease and T1D Today, the U.S. Food and Drug Administration (FDA) approved finerenone (brand name Kerendia) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D). UACR is a measure of kidney damage, and reducing […]

What’s Happening? In an exciting update for the type 1 diabetes (T1D) community, Tzield—the first disease-modifying therapy approved by the FDA to delay progression of stage 2 T1D—has now been approved by the FDA for use in stage 3 T1D. People aged 8-17 with stage 3 T1D will soon be able to get Tzield in clinics (with a prescription) if […]

Afrezza, a rapid-acting, inhaled mealtime insulin, has been approved by the FDA for use in children and adolescents ages 6+ with T1D.

From March 15–18, more than 200 passionate, motivated Breakthrough T1D Advocates from all 50 states convened in Washington, D.C., for Breakthrough T1D 2026 Government Day. Government Day remains one of Breakthrough T1D’s most impactful ways to effect change. By bringing the lived type 1 diabetes (T1D) experience directly to policymakers, we are accelerating progress toward […]

Nearly 3 years after Breakthrough T1D joined forces with Civica, a non-profit pharmaceutical company, its first insulin is now available for purchase at pharmacies across the country. Check out our story from October that highlights the years of partnership between Civica and Breakthrough T1D that made today a reality. We worked with our partners at […]

What is the pipeline? Every new medical device, therapy, treatment, and drug—including those for type 1 diabetes (T1D)—goes through the drug development pipeline. Getting a new therapy or device from the earliest stages of research eventually into the hands of people with T1D is a complicated process. Science takes time (from years to decades!), money […]

This past week, the FDA and Sanofi, the maker of Tzield, made an important announcement. Tzield, the first disease-modifying therapy approved for delaying onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D, has been accepted into the FDA Commissioner’s National Priority Voucher (CNPV) program for people with stage 3 T1D. […]

Nearly 3 years ago, Breakthrough T1D joined forces with Civica Rx, a non-profit pharmaceutical company, to manufacture and distribute low-cost insulins. Starting on January 1, 2026, the first of those insulins, insulin glargine-yfgn (a long-acting insulin interchangeable with Lantus®), will be available for purchase. 5 pens, no more than $55 – for anyone While we […]

Breakthrough T1D recently published two peer-reviewed journal articles. One detailed burdensome unmet needs in the T1D community and identified key steps we can take to meet these needs. The other used real-world data to better understand American T1D demographics and predict changes in the next decade.

Breakthrough T1D is funding research that supports manufactured islet cell source, survival, and protection and is also driving initiatives to unlock access to manufactured islet therapies for people with T1D.